PhaseRx, Inc. IPO Research Information

PhaseRx, Inc. IPO Advisory

Share this IPO Profile:

Smart Search

For IPO Boutique's "scale of 1 to 5" BUY rating on PhaseRx, Inc., and our comprehensive analysis, click "Buy Market Research".

Company	Symbol	Price Range	Issue Price	Open	Shares	Trade Date
PhaseRx, Inc.	PZRX - NASDAQ	$5.00-$7.00	$5.00	$5.50	3.7 million	5/18/2016
Underwriter(s): Laidlaw & Co., Roth Capital Partners
Co-Manager(s):
Industry: Health Care
Filing(s): Filed 2016-04-18 Terms Added 2016-05-02

PhaseRx, Inc. Quote & Chart - Click for current quote - PZRX

About PhaseRx, Inc. (adapted from PhaseRx, Inc. prospectus):
They are a preclinical biopharmaceutical company developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy, or i-ERT, and expect to generate clinical safety and efficacy data in 2018.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.

IPO Boutique aggregates information on public companies and private companies, such as "PZRX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.